THERAPEUTICSMD INC (TXMD) Forecast, Price Target & Analyst Ratings
NASDAQ:TXMD • US88338N2062
2.22 USD
-0.02 (-0.89%)
Last: Mar 3, 2026, 08:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for THERAPEUTICSMD INC (TXMD).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateMar 25, 2026
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.22 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
TXMD was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about TXMD.
In the previous month the buy percentage consensus was at a similar level.
TXMD was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-17 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-01-11 | Cantor Fitzgerald | Reiterate | Neutral |
| 2022-07-13 | Cantor Fitzgerald | Reiterate | Neutral |
| 2022-06-07 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-05-06 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2022-03-11 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-12 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 25, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 69.96M 2,622.18% | 1.302M -98.14% | 1.761M 35.25% | 9.282M 427.09% | 9.486M 2.20% | 9.69M 2.15% | 9.894M 2.11% | 10.098M 2.06% | 10.2M 1.01% | |
| EBITDA YoY % growth | 11.85M 115.03% | -7.601M -164.14% | -2.983M 60.76% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 10.66M 113.40% | -8.523M -179.95% | -3.492M 59.03% | 4.998M 243.13% | 2.448M -51.02% | 2.754M 12.50% | 3.06M 11.11% | 3.264M 6.67% | 3.468M 6.25% | |
| Operating Margin | 15.24% | -654.61% | -198.30% | 53.85% | 25.81% | 28.42% | 30.93% | 32.32% | 34.00% | |
| EPS YoY % growth | 11.80 154.88% | N/A -103.28% | N/A 192.11% | 0.36 | 0.17 -51.43% | 0.19 11.76% | 0.20 5.26% | 0.22 10.00% | 0.23 4.55% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-18.42%
EPS Next 5 Year
-8.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1.82%
Revenue Next 5 Year
1.92%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
THERAPEUTICSMD INC / TXMD Forecast FAQ
When does THERAPEUTICSMD INC (TXMD) report earnings?
THERAPEUTICSMD INC (TXMD) will report earnings on 2026-03-25, after the market close.
Can you provide the analyst count for THERAPEUTICSMD INC stock?
The number of analysts covering THERAPEUTICSMD INC (TXMD) is 6.